Galenica successfully places a bond of over CHF 100 million – Biotech Investments

Galenica AG

/ Key word(s): Bond

Galenica successfully places a bond of over CHF 100 million

16.04.2024 / 18:05 CET/CEST

Press release

Today, Galenica successfully placed a fixed rate bond of over CHF 100 million.

The bond has a term of 7 years and an annual coupon of 1.65%. The proceeds from the transaction will be used for general corporate purposes. With this new bond, Galenica is reducing its short-term financial liabilities and securing its long-term financing. The term until 2031 ideally complements the terms of the outstanding bonds from 2026 (CHF 180 million, coupon 1.0%) and 2029 (CHF 240 million, coupon 2.35%).

UBS and Zürcher Kantonalbank are joint lead manager for this issue. An application for admission to trading on the SIX Swiss Exchange for the bond is being made.

Dates for the diary

23 May 2024	Galenica Group sales update
6 August 2024	Galenica Group half-year results 2024
24 October 2024	Galenica Group sales update

For further information, please contact:

Welcome to the Galenica network!
Our ambition is to meet the needs of patients and customers in the Swiss healthcare market in a seamless, efficient and personalised way. To achieve this, we operate the Galenica network with over 20 Business Units, the strongest partners in the Swiss healthcare market. We offer fully integrated solutions both for customers and patients as well as for pharmacies, drugstores, medical practices, hospitals, retirement and nursing homes, home care providers, wholesalers, pharmaceutical companies, health insurance funds and other partners.
Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information concerning Galenica can be found at www.galenica.com.

End of Media Release

Smartphone app uses AI and facial-image processing software to reliably detect the onset of depression

Dartmouth researchers report they have developed the first smartphone application that uses artificial intelligence paired with facial-image processing software to reliably detect the onset of

February 27, 2024

House Republicans abandon PBM reform in push to keep government open

WASHINGTON — House Republicans have abandoned an effort to include reforms to pharmacy benefit managers in an end-of-year bill to fund the federal government. Congressional leaders

December 19, 2024

Pharmalittle: We’re reading about Pfizer’s new R&D head, Merck and J&J job cuts in China, and more

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After

November 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.